PriceTargets.com logo

Microbix Biosystems - MBX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$0.33 As of 04/26/2024 01:00 AM ET
▼ -0.02 (-5.80%)

This chart shows the closing price for MBX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Microbix Biosystems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MBX

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Microbix Biosystems in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$0.33.

This chart shows the closing price for MBX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Microbix Biosystems. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/4/2024Bloom BurtonReiterated RatingBuy
6/6/2022Bloom BurtonReiterated RatingBuy
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.92 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Microbix Biosystems logo
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: C$0.33
Low: C$0.32
High: C$0.34

50 Day Range

MA: C$0.38
Low: C$0.34
High: C$0.41

52 Week Range

Now: C$0.33
Low: C$0.23
High: C$0.47

Volume

166,766 shs

Average Volume

71,155 shs

Market Capitalization

C$44.38 million

P/E Ratio

10.83

Dividend Yield

2.30%

Beta

0.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Microbix Biosystems?

The following Wall Street research analysts have issued stock ratings on Microbix Biosystems in the last twelve months: Bloom Burton.
View the latest analyst ratings for MBX.

What is the current price target for Microbix Biosystems?

0 Wall Street analysts have set twelve-month price targets for Microbix Biosystems in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Microbix Biosystems in the next year.
View the latest price targets for MBX.

What is the current consensus analyst rating for Microbix Biosystems?

Microbix Biosystems currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MBX will outperform the market and that investors should add to their positions of Microbix Biosystems.
View the latest ratings for MBX.

What other companies compete with Microbix Biosystems?

Other companies that are similar to Microbix Biosystems include Helix BioPharma, BriaCell Therapeutics, Small Pharma, ProMIS Neurosciences and Emerald Health Therapeutics. Learn More about companies similar to Microbix Biosystems.

How do I contact Microbix Biosystems' investor relations team?

Microbix Biosystems' physical mailing address is 265 Watline Ave, MISSISSAUGA, ON L4Z 1P3, Canada. The company's listed phone number is +1-905-3618910. The official website for Microbix Biosystems is microbix.com. Learn More about contacing Microbix Biosystems investor relations.